gutflix
GI learning, personalised

Summary

TARGET ACHIEVEMENT AFTER 32 WEEKS OF VEDOLIZUMAB TREATMENT IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: AN INTERIM ANALYSIS FROM THE VERDICT TRIAL

Simon Travis

UEG Week Vienna 2024 | Poster

IBD

October 13, 2024

Interim results from the VERDICT trial show that vedolizumab achieves corticosteroid-free remission in 52 to 82 percent of ulcerative colitis patients by week 32, with higher success rates for less stringent treatment targets and in bionaïve patients.

KEY POINTS

- The VERDICT trial randomized 612 moderately-to-severely active ulcerative colitis patients to three treatment targets: symptomatic remission alone (Group 1), symptomatic plus endoscopic remission (Group 2), or disease clearance including histologic remission (Group 3), all using vedolizumab without week 10 dosing or early dose escalation.
- By week 32 in the intention-to-treat population, corticosteroid-free remission was achieved in 51.9 percent of Group 1, 43.9 percent of Group 2, and 43.1 percent of Group 3 patients.
- Bionaïve patients showed substantially higher remission rates at week 32 (65.5 percent, 49.7 percent, and 46.5 percent across Groups 1, 2, and 3) compared to bio-exposed patients (18.2 percent, 26.5 percent, and 25.6 percent).
- Among patients with observed week 32 data, remission rates were 81.6 percent for Group 1, 61.7 percent for Group 2, and 53.3 percent for Group 3, demonstrating improvement from week 16 to week 32 across all treatment targets.
- These interim findings are relevant to gastroenterologists managing moderate-to-severe ulcerative colitis and considering treatment targets for vedolizumab therapy.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/98839778-9110-11ef-84c2-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.